Abstract
Mitotic arrest deficient 2 (MAD2) is thought to be a key component of the mitotic checkpoint, which ensures accurate chromosome segregation. Reduced expression of MAD2 protein is associated with mitotic checkpoint abrogation and chromosomal instability in certain types of human cancers. To explore the possibility of developing a novel strategy for the treatment of cancer based on selective killing of mitotic checkpoint-defective or -competent cells, here we have investigated the effect of MAD2 expression on cellular sensitivity to checkpoint-targeting anticancer drugs. We reintroduced MAD2 protein in a mitotic checkpoint-defective nasopharyngeal carcinoma cell line, CNE2, using an inducible expression vector. We found that overexpression of MAD2 led to an increased sensitivity to vincristine, which was accompanied by increased mitotic index and G2/M cell cycle arrest. In addition, increased phosphorylation of Raf, MEK1/2 and Bcl-2 was observed in MAD2-overexpressing cells in response to vincristine. Furthermore, inhibition of phosphorylation of MEK1/2 by its inhibitor PD098059 led to reduced sensitivity to vincristine, which was associated with decreased Bcl-2 phosphorylation. Our data suggest a role for MAD2 in the sensitization of cancer cells to certain mitotic checkpoint-targeting anticancer drugs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amon A . (1999). Curr. Opin. Genet. Dev., 9, 69–75.
Blagosklonny MV, Giannakakou P, el Deiry WS, Kingston DG, Higgs PI, Neckers L, Fojo T . (1997). Cancer Res., 57, 130–135.
Brichese L, Barboule N, Heliez C, Valette A . (2002). Exp. Cell. Res., 278, 101–111.
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B . (1998). Nature, 392, 300.
Dimmeler S, Breitschopf K, Haendeler J, Zeiher AM . (1999). J Exp Med, 189, 1815–1818
Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK . (2000). Cell, 101, 635–645.
Fan M, Du L, Stone AA, Gilbert KM, Chambers TC . (2000). Cancer Res., 60, 6403–6407.
Haldar S, Jena N, Croce CM . (1995). Proc. Natt. Acad. Sci. USA, 92, 4507–4611.
Hayne C, Tzivion G, Luo Z . (2000). J. Biol. Chem., 275, 31876–31882.
Huang ST, Cidlowski JA . (2002). FASEB J., 16, 825–832.
Huang Y, Sheikh MS, Fomace AJ, Holbrook NJ . (1999). Oncogene, 18, 3431–3439.
Jin DY, Spencer F, Jeang KT . (1998). Cell, 93, 81–91.
Jordan MA, Wendell K, Gardiner S, Deny WB, Copp H, Wilson L . (1996). Cancer Res., 56, 816–825.
Kallio M, Weinstein J, Daum JR, Burke DJ, Gorbsky, GJ . (1998). J. Cell Biol., 141, 1393–1406.
Kasai T, Iwanaga Y, Iha H, Jeang KT . (2002). J. Biol. Chem., 277, 5187–5193.
Laird AD, Taylor SJ, Oberst M, Shalloway D . (1995). J. Biol. Chem., 270, 26742–26745.
Lengauer C, Kinzler KW, Vogelstein B . (1998). Nature, 396, 643–649.
Li Y, Benezra R . (1996). Science, 274, 246–248.
Lovric J, Moelling K . (1996). Oncogene, 12, 1109–1116.
Minn AJ, Boise LH, Thompson CB . (1996). Genes Dev., 10, 2621–2631.
Minshull J, Sun H, Tonks NK, Murray AW . (1994). Cell, 79, 475–486.
Pennisi E . (1998). Science, 279, 477–478.
Sherwood SW, Sheridan JP, Schimke RT . (1994). Exp. Cell Res., 215, 373–379.
Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL . (1998). Mol Cell. Bio., 18, 3509–3617.
Stadheim TA, Xiao H, Eastman A . (2001). Cancer Res., 61, 1533–1540.
Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, Takahashi T . (1999). Oncogene, 18, 4295.
Takenaka K, Gotoh Y, Nishida E . (1997). J. Cell Biol., 136, 1091–1097.
Takenaka K, Moriguchi T, Nishida E . (1998). Science, 280, 599–602.
Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA . (1996). Nat. Med., 2, 72–79.
Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena JJ . (1999). Biol Chem., 274, 8208–8216.
Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL, Tsao SW . (2002). Cancer Res., 62, 1662–1668.
Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, Liu Y, Tsao SW . (2000). Carcinogenesis, 21, 2293–2297.
Wang X, Liu Y, Chow LS, Wong SC, Tsao SW, Kwong DL, Wang J, Sham JS, Nicholls JM . (1999). Int. J. Oncol., 15, 1097–1102.
Wang X, Wong SC, Pan J, Tsao SW, Fung KH, Kwong DL, Sham JS, Nicholls JM . (1998). Cancer Res., 58, 5019–5022.
Wang X, Zhai Y, Ferrell Jr JE (1997). J. Cell Biol., 137, 433–443.
Wassmann K, Benezra R . (2001). Curr. Opin. Genet. Dev., 11, 83–90.
Yamamoto K, Ichijo H, Korsmeyer SJ . (1999). Mol. Cell Biol., 19, 8469–8478
Yeung K, Seitz T Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, SedivyJM, Kolch W (1999). Nature, 401, 173–177.
Zhang Y, Lees E . (2001). Mol. Cell. Biol., 21, 5190–5199.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, X., Jin, DY., Wong, H. et al. MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene 22, 109–116 (2003). https://doi.org/10.1038/sj.onc.1206069
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206069
Keywords
This article is cited by
-
Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells
Apoptosis (2019)
-
p31comet inactivates the chemically induced Mad2-dependent spindle assembly checkpoint and leads to resistance to anti-mitotic drugs
SpringerPlus (2013)
-
Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin
Tumor Biology (2010)
-
Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
British Journal of Cancer (2006)
-
Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45
Cancer Chemotherapy and Pharmacology (2006)